Elos Medtech Interim Report January 1 – June 30, 2023

April – June 2023

• Net sales for the second quarter amounted to SEK 269.8 (233.1) million, an increase of 15.8 percent compared to the same quarter last year. Net sales in local currencies increased by 9.5 percent.
• Operating profit amounted to SEK 30.1 (37.8) million, corresponding to an operating margin of 11.2 (16.2) percent.
• Profit after net financial items amounted to SEK 13.7 (38.8) million. Net financial items were negatively affected by exchange rate differences of SEK -8.6 (3.6) million and totaled SEK -16.4 (1.1) million.
• Cash flow from operating activities was SEK 34.6 (26.4) million, and SEK 2.0 (-3.8) million after investments.
• Earnings per share amounted to SEK 1.16 (3.68).

For further information, please contact:
Stefano Alfonsi, President and CEO, +44 772 04 98 342 , e-mail: stefano.alfonsi@elosmedtech.com
Ewa Linsäter, Group CFO, +46 76 633 32 33, e-mail: ewa.linsater@elosmedtech.com

This disclosure contains information that Elos Medtech AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and the Swedish Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above on July 14, 2023, at 15:00 (CEST).

For additional information about the Elos Medtech Group, visit www.elosmedtech.com

Tags: